STOCK TITAN

[Form 4] Shuttle Pharmaceuticals Holdings, Inc. Insider Trading Activity

(Neutral)
(Positive)
Form Type
4

Rhea-AI Filing Summary

HRT Financial LP, a ten percent owner of Shuttle Pharmaceuticals Holdings, Inc., reported two open-market purchases of common stock. On July 9, 2026 it bought 8,266 shares at $3.38 per share, and on July 10, 2026 it bought 731 shares at $3.11 per share. Following these transactions, HRT Financial LP directly held 61,271 shares of Shuttle Pharmaceuticals common stock.

Positive

  • None.

Negative

  • None.

Filing Explained

Two open-market purchases raised the reporting person’s direct common-stock holdings to 61,271 shares.

Form 4 reports an insider’s transaction within two business days, and this July 13, 2026 filing reports two common-stock purchases by Adam Nunes. The purchases occurred on July 9, 2026 and July 10, 2026, for 8,266 shares at $3.38 and 731 shares at $3.11, respectively.

Both transactions use code P, which identifies them as open-market purchases. The reporting person’s direct holdings were 60,540 shares after the first transaction and 61,271 shares after the second.

The disclosure therefore changes the reporting person’s stated direct ownership position and records acquisitions, rather than a grant, derivative exercise, or tax-withholding transaction.

Insider HRT FINANCIAL LP
Role 10% Owner
Bought 8,997 shs ($30K)
Type Security Shares Price Value
Purchase Common Stock 731 $3.11 $2K
Purchase Common Stock 8,266 $3.38 $28K
Holdings After Transaction: Common Stock — 61,271 shares (Direct)
Footnotes (1)

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
HRT FINANCIAL LP

(Last)(First)(Middle)
3 WORLD TRADE CENTER, 175 GREENWICH STRE
76TH FLOOR

(Street)
NEW YORK NEW YORK 10007

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Shuttle Pharmaceuticals Holdings, Inc. [ SHPH ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
DirectorX10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/09/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock07/09/2026P8,266A$3.3860,540D
Common Stock07/10/2026P731A$3.1161,271D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
Adam Nunes07/13/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)